SG10201601909TA - Combination Therapies For Hematologic Malignancies - Google Patents
Combination Therapies For Hematologic MalignanciesInfo
- Publication number
- SG10201601909TA SG10201601909TA SG10201601909TA SG10201601909TA SG10201601909TA SG 10201601909T A SG10201601909T A SG 10201601909TA SG 10201601909T A SG10201601909T A SG 10201601909TA SG 10201601909T A SG10201601909T A SG 10201601909TA SG 10201601909T A SG10201601909T A SG 10201601909TA
- Authority
- SG
- Singapore
- Prior art keywords
- combination therapies
- hematologic malignancies
- hematologic
- malignancies
- therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452034P | 2011-03-11 | 2011-03-11 | |
| US201161493317P | 2011-06-03 | 2011-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201601909TA true SG10201601909TA (en) | 2016-04-28 |
Family
ID=45888489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013067129A SG193337A1 (en) | 2011-03-11 | 2012-03-09 | Combination therapies for hematologic malignancies |
| SG10201601909TA SG10201601909TA (en) | 2011-03-11 | 2012-03-09 | Combination Therapies For Hematologic Malignancies |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013067129A SG193337A1 (en) | 2011-03-11 | 2012-03-09 | Combination therapies for hematologic malignancies |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20130064812A1 (en) |
| EP (2) | EP2683377A1 (en) |
| JP (2) | JP2014510729A (en) |
| KR (1) | KR20140022836A (en) |
| CN (1) | CN103826629A (en) |
| AP (1) | AP2013007158A0 (en) |
| AR (1) | AR085668A1 (en) |
| AU (2) | AU2012229266A1 (en) |
| BR (1) | BR112013022801A2 (en) |
| CA (1) | CA2829096A1 (en) |
| CL (1) | CL2013002552A1 (en) |
| CO (1) | CO6821936A2 (en) |
| CR (1) | CR20130517A (en) |
| EA (1) | EA201391263A1 (en) |
| EC (1) | ECSP13012964A (en) |
| MA (1) | MA35090B1 (en) |
| MX (1) | MX2013010439A (en) |
| PE (1) | PE20140405A1 (en) |
| SG (2) | SG193337A1 (en) |
| TW (1) | TW201242598A (en) |
| UY (1) | UY33947A (en) |
| WO (1) | WO2012125510A1 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1951281B1 (en) | 2005-10-17 | 2015-04-15 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| PL2010209T3 (en) | 2006-04-10 | 2017-04-28 | Sloan Kettering Inst For Cancer Res | Immunogenic wt-1 peptides and methods of use thereof |
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| SG187425A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
| NZ592880A (en) | 2008-11-13 | 2013-06-28 | Gilead Calistoga Llc | Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| PE20141303A1 (en) | 2011-01-10 | 2014-10-01 | Infinity Pharmaceuticals Inc | PROCEDURE FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
| CN108676069A (en) | 2012-01-13 | 2018-10-19 | 纪念斯隆凯特林癌症中心 | Immunogenicity WT-1 peptides and its application method |
| EP2916868B1 (en) | 2012-11-08 | 2022-05-11 | Rhizen Pharmaceuticals S.A. | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| EP3769782A1 (en) | 2013-01-15 | 2021-01-27 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| CA2905588C (en) * | 2013-03-12 | 2018-11-06 | Sumitomo Dainippon Pharma Co., Ltd. | Liquid aqueous composition |
| CN103271897A (en) * | 2013-06-04 | 2013-09-04 | 李春启 | Applications of mesna in preparation of anti-angiogenesis drugs |
| ES2535452B1 (en) * | 2013-08-02 | 2016-03-02 | Dalana3 S.L. | Enhancement of the effect of methotrexate through combined use with lipophilic statins |
| CA2931615A1 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| WO2015160975A2 (en) * | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| DK3148532T3 (en) | 2014-05-28 | 2021-04-26 | Piramal Entpr Ltd | Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer |
| WO2016001855A1 (en) | 2014-07-04 | 2016-01-07 | Lupin Limited | Quinolizinone derivatives as pi3k inhibitors |
| CN105380956B (en) * | 2015-11-04 | 2017-12-19 | 张陆军 | A kind of pharmaceutical composition of Dana Delany containing Chinese mugwort for treating leukaemia and application |
| MX2018016227A (en) | 2016-06-24 | 2019-07-08 | Infinity Pharmaceuticals Inc | Combination therapies. |
| EP3717915B1 (en) | 2017-11-30 | 2024-04-10 | Singapore Health Services Pte. Ltd. | A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient |
| TWI820146B (en) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | Purinone compounds and their use in treating cancer |
| CN112569342A (en) * | 2020-12-21 | 2021-03-30 | 中南大学 | Application of caspofungin and/or pharmaceutical salt thereof in preparation of antitumor drugs and antitumor drugs |
| CN116019798B (en) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | Application of phenylacetylglutamine in preparation of medicines for preventing and/or treating cardiotoxicity caused by doxorubicin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1755609A1 (en) * | 2004-05-25 | 2007-02-28 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| NZ592880A (en) * | 2008-11-13 | 2013-06-28 | Gilead Calistoga Llc | Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy |
| EP2421536B1 (en) * | 2009-04-20 | 2015-08-26 | Gilead Calistoga LLC | Methods of treatment for solid tumors |
| MX342405B (en) * | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | The use of inhibitors of bruton's tyrosine kinase (btk). |
-
2012
- 2012-03-09 EA EA201391263A patent/EA201391263A1/en unknown
- 2012-03-09 JP JP2013557934A patent/JP2014510729A/en active Pending
- 2012-03-09 AP AP2013007158A patent/AP2013007158A0/en unknown
- 2012-03-09 BR BR112013022801A patent/BR112013022801A2/en not_active IP Right Cessation
- 2012-03-09 SG SG2013067129A patent/SG193337A1/en unknown
- 2012-03-09 PE PE2013002034A patent/PE20140405A1/en not_active Application Discontinuation
- 2012-03-09 WO PCT/US2012/028654 patent/WO2012125510A1/en active Application Filing
- 2012-03-09 CA CA2829096A patent/CA2829096A1/en not_active Abandoned
- 2012-03-09 KR KR1020137026766A patent/KR20140022836A/en not_active Application Discontinuation
- 2012-03-09 MX MX2013010439A patent/MX2013010439A/en not_active Application Discontinuation
- 2012-03-09 US US13/417,180 patent/US20130064812A1/en not_active Abandoned
- 2012-03-09 SG SG10201601909TA patent/SG10201601909TA/en unknown
- 2012-03-09 EP EP12710838.9A patent/EP2683377A1/en not_active Withdrawn
- 2012-03-09 CN CN201280022394.XA patent/CN103826629A/en active Pending
- 2012-03-09 AU AU2012229266A patent/AU2012229266A1/en not_active Abandoned
- 2012-03-09 EP EP17157706.7A patent/EP3187184A1/en not_active Withdrawn
- 2012-03-12 UY UY0001033947A patent/UY33947A/en not_active Application Discontinuation
- 2012-03-12 TW TW101108394A patent/TW201242598A/en unknown
- 2012-03-12 AR ARP120100805A patent/AR085668A1/en unknown
-
2013
- 2013-09-05 CL CL2013002552A patent/CL2013002552A1/en unknown
- 2013-09-30 CO CO13231986A patent/CO6821936A2/en not_active Application Discontinuation
- 2013-10-03 MA MA36292A patent/MA35090B1/en unknown
- 2013-10-08 CR CR20130517A patent/CR20130517A/en unknown
- 2013-10-10 EC ECSP13012964 patent/ECSP13012964A/en unknown
-
2015
- 2015-01-16 US US14/599,287 patent/US20150196564A1/en not_active Abandoned
-
2016
- 2016-06-30 US US15/199,666 patent/US20170119771A1/en not_active Abandoned
- 2016-07-27 JP JP2016147201A patent/JP2016222700A/en active Pending
- 2016-09-16 AU AU2016228272A patent/AU2016228272A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG193337A1 (en) | 2013-10-30 |
| US20130064812A1 (en) | 2013-03-14 |
| US20170119771A1 (en) | 2017-05-04 |
| AP2013007158A0 (en) | 2013-10-31 |
| PE20140405A1 (en) | 2014-03-22 |
| CO6821936A2 (en) | 2013-12-31 |
| AU2012229266A1 (en) | 2013-05-02 |
| UY33947A (en) | 2012-10-31 |
| CR20130517A (en) | 2014-02-12 |
| TW201242598A (en) | 2012-11-01 |
| KR20140022836A (en) | 2014-02-25 |
| JP2016222700A (en) | 2016-12-28 |
| ECSP13012964A (en) | 2014-02-28 |
| US20150196564A1 (en) | 2015-07-16 |
| CN103826629A (en) | 2014-05-28 |
| EP2683377A1 (en) | 2014-01-15 |
| MA35090B1 (en) | 2014-05-02 |
| CL2013002552A1 (en) | 2014-09-05 |
| MX2013010439A (en) | 2014-07-09 |
| CA2829096A1 (en) | 2012-09-20 |
| EA201391263A1 (en) | 2014-06-30 |
| BR112013022801A2 (en) | 2019-09-24 |
| JP2014510729A (en) | 2014-05-01 |
| EP3187184A1 (en) | 2017-07-05 |
| WO2012125510A1 (en) | 2012-09-20 |
| AU2016228272A1 (en) | 2016-10-06 |
| AR085668A1 (en) | 2013-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2013007158A0 (en) | Combination therapies for hematologic malignancies | |
| HRP20181526T1 (en) | Combination therapy for ischemia | |
| PT2755785E (en) | Cutting insert | |
| GB2503880B (en) | Insert for pipes | |
| EP2707741A4 (en) | Direction-enhanced navigation | |
| GB201203623D0 (en) | Insert | |
| PT2726773T (en) | Improved boss for composite container | |
| IL228095A0 (en) | Combination therapies comprising anti-erbb3 agents | |
| EP2914254A4 (en) | Combination therapies | |
| SI2793866T1 (en) | New combination | |
| EP2699237A4 (en) | Therapy for leukemia | |
| PL2723344T3 (en) | Monoterpene-containing agent for combination therapy | |
| GB2497137B (en) | Highly linear - gain oscillator | |
| PL2683510T3 (en) | Cutting insert | |
| EP2720718A4 (en) | Anti-cd3 therapies | |
| HK1200354A1 (en) | Combination therapy for chemoresistant cancers | |
| EP2751047A4 (en) | Cutting insert | |
| GB2504263B (en) | Synergistic therapies for neuroprotection | |
| GB201106010D0 (en) | Insert | |
| GB201118153D0 (en) | Therapies for cancers | |
| PL120345U1 (en) | Device for supplying inserts | |
| ZA201403872B (en) | New combination | |
| PL2780128T3 (en) | Cutting insert | |
| GB201214493D0 (en) | Therapies | |
| GB201110186D0 (en) | Accessories for bags |